Trial Profile
A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Mavrilimumab (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Kiniksa Pharmaceuticals
- 09 Mar 2022 Results published in the Annals of the Rheumatic Diseases
- 09 Nov 2021 Results of post hoc analysis assessing the CRP and ESR levels from randomization through Wk 26 in patients with and without relapse by treatment arm presented at the ACR Convergence 2021
- 01 Nov 2021 According to a Kiniksa Pharmaceuticals media release, data from this trial will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2021.